December 14, 2022
Meiji Seika Pharma said on December 13 that it has launched a PIII clinical study in Japan for ARCT-154, a next-generation mRNA vaccine against COVID-19 being developed by US biotech Arcturus Therapeutics. Meiji Pharma is still in talks with Arcturus...read more